Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy

Aron Goldhirsch, Urs Leuenberger, Hans Jörg Ryssel, Franco Cavalli, Roland W. Sonntag, Rudolph A. Joss, Kurt W. Brunner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.

Original languageEnglish
Pages (from-to)284-286
Number of pages3
JournalOncology
Volume39
Issue number5
DOIs
Publication statusPublished - 1982

Fingerprint

Fluoxymesterone
Tamoxifen
Breast Neoplasms
Recurrence
Population

Keywords

  • Advanced breast cancer
  • Combination hormonotherapy
  • Tamoxifen Fluoxymesterone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy. / Goldhirsch, Aron; Leuenberger, Urs; Ryssel, Hans Jörg; Cavalli, Franco; Sonntag, Roland W.; Joss, Rudolph A.; Brunner, Kurt W.

In: Oncology, Vol. 39, No. 5, 1982, p. 284-286.

Research output: Contribution to journalArticle

Goldhirsch, Aron ; Leuenberger, Urs ; Ryssel, Hans Jörg ; Cavalli, Franco ; Sonntag, Roland W. ; Joss, Rudolph A. ; Brunner, Kurt W. / Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy. In: Oncology. 1982 ; Vol. 39, No. 5. pp. 284-286.
@article{bd7eafbbfbbc43d99b91418e3f5cf164,
title = "Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy",
abstract = "33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27{\%}) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50{\%}) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18{\%} for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.",
keywords = "Advanced breast cancer, Combination hormonotherapy, Tamoxifen Fluoxymesterone",
author = "Aron Goldhirsch and Urs Leuenberger and Ryssel, {Hans J{\"o}rg} and Franco Cavalli and Sonntag, {Roland W.} and Joss, {Rudolph A.} and Brunner, {Kurt W.}",
year = "1982",
doi = "10.1159/000225652",
language = "English",
volume = "39",
pages = "284--286",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

TY - JOUR

T1 - Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy

AU - Goldhirsch, Aron

AU - Leuenberger, Urs

AU - Ryssel, Hans Jörg

AU - Cavalli, Franco

AU - Sonntag, Roland W.

AU - Joss, Rudolph A.

AU - Brunner, Kurt W.

PY - 1982

Y1 - 1982

N2 - 33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.

AB - 33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.

KW - Advanced breast cancer

KW - Combination hormonotherapy

KW - Tamoxifen Fluoxymesterone

UR - http://www.scopus.com/inward/record.url?scp=0019986774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019986774&partnerID=8YFLogxK

U2 - 10.1159/000225652

DO - 10.1159/000225652

M3 - Article

VL - 39

SP - 284

EP - 286

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -